RE: 5m for each additional usage too23 May 2020 15:28
Uinisonm 12.53pm, thats what intrigued me with that RNS and perked my interest further. In addition push into antivirals arena is a good move. As for Lupuzor, BoD acknowledged design flaws in the IMM trials. The data, structure and design from these trials will have been reviewed in an extensive due diligence by Avion (who have far more knowledge and expertise than anyone on this board), prior to them coming on board and then to have the confidence to fund the new trials and laydown licencing parameters etc. Shows their belief in the drug and their confidence of success .
So, I completely disagree with anyone who says Lupuzor is a failed drug. The context is very imperative here.